Gerresheimer stock holds steady as investors await fresh numbers.
Published on 07/19/2026 at 20:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gerresheimer stock stays anchored to its latest evidenced report figures, with Gerresheimer AG (ISIN DE000A0LD6E6) still judged through prior operating results, balance-sheet leverage, and market valuation context rather than a new catalyst.
Latest figures matter
The company reported revenue of EUR 2.04 billion in fiscal 2025, while adjusted EBITDA came in at EUR 430.0 million and the adjusted EBITDA margin reached 21.1% in the same period. Net debt stood at EUR 1.28 billion at fiscal-year end 2025, a level that keeps financing conditions and cash generation relevant for valuation work.
That combination leaves investors focused on the relationship between growth and leverage. A margin of 21.1% against EUR 2.04 billion of sales gives a clear operating base, but EUR 1.28 billion of net debt means the balance sheet still matters when the market re-rates the shares.
Revenue up, leverage still visible
In fiscal 2025, the company’s EUR 2.04 billion revenue base and EUR 430.0 million adjusted EBITDA show a business that remained profitable on an adjusted basis. The margin of 21.1% is the most compact read-through for the year, because it links sales directly to earnings quality.
Net debt of EUR 1.28 billion at 31 December 2025 is the second anchor. It makes cash conversion, working capital discipline, and the pace of earnings delivery central to the stock narrative.
Market value frame
For the market frame, the stock should be read against its most recent available valuation context, not just against the income statement. With no new evidence in this call, the price line is omitted and the focus stays on the reported 2025 numbers and the financing profile that they imply.
That is still enough to frame the debate: 2025 revenue of EUR 2.04 billion, adjusted EBITDA of EUR 430.0 million, and net debt of EUR 1.28 billion define the current operating and financial picture.
Pharma packaging business
Gerresheimer’s packaging and containment business remains the core reference point for investors because it links directly to the company’s earnings mix and margin profile. The pharmaceutical packaging franchise is the part of the group most often used to judge pricing power and customer stickiness.
In fiscal 2025, that business model translated into the EUR 430.0 million adjusted EBITDA result and the 21.1% margin, which are the two figures that matter most for the quality of earnings. A business that can sustain those levels is judged differently from one that only expands sales.
Stock level anchor
The stock currently needs a fresh market quote or a new company update to move beyond its latest reported numbers. Until then, the most relevant read remains fiscal 2025: EUR 2.04 billion revenue, EUR 430.0 million adjusted EBITDA, and EUR 1.28 billion net debt.
Gerresheimer key facts
- Company: Gerresheimer AG
- ISIN: DE000A0LD6E6
- Ticker: XETRA: GXI
- Trading venue: Xetra
- Sector / Industry: Health Care Equipment / Health Care Containers and Packaging
- Index membership: MDAX
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
